News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
FDA
EU Backs Nycomed’s Daxas In Deadly Lung Disease; Drug Approval Could Spur Nycomed IPO
July 6, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
ZURICH July 6 (Reuters) - Nycomed's [NYCMD.UL] lung drug Daxas has won European Union backing to treat patients with chronic obstructive pulmonary disease, bringing to market the first new type of treatment for the disease in over a decade.
Twitter
LinkedIn
Facebook
Email
Print
FDA
Approvals
Europe
MORE ON THIS TOPIC
Legal
Judge Rules Against Semaglutide Compounders After Shortage Declared Over
April 25, 2025
·
2 min read
·
Tristan Manalac
Vaccines
After Missed Decision Deadline, Novavax Says COVID-19 Shot ‘Approvable’
April 24, 2025
·
2 min read
·
Tristan Manalac
Regulatory
Vanda Escalates Vendetta Against FDA, Blasts ‘Bureaucrats’ for Delaying Stomach Drug
April 24, 2025
·
2 min read
·
Tristan Manalac
Layoffs
Guessing Game: Former HHS Workers’ Next Stops Unclear
April 24, 2025
·
5 min read
·
Angela Gabriel